1. Giant Cell Arteritis: Timely Diagnosis and Emerging Treatment Strategies

2. Overview of GCA

3. Overview of GCA (cont)

4. Epidemiologic Factors Related to GCA

5. Headache

6. Visual Signs and Symptoms

7. Optic Disc in GCA

8. Vision Loss in GCA

9. Jaw Claudication

10. The PMR Connection

11. Diagnosing GCA

12. Normal TA, 4X, H&E Stain

13. Normal TA, 4X, Elastin Stain

14. TA, 4X, H&E Stain: Evidence of Arteritis

15. TA, 4X, Elastin Stain: Evidence of Arteritis

16. Ultrasound: Normal TA, Right Parietal Ramus

17. Ultrasound: Normal Right Parietal Ramus

18. Ultrasound: Hypoechoic Circumferential Wall Thickening Due to Vasculitic Wall Edema -- Halo Sign

19. Ultrasound: Left Mid-Subclavian Artery With Hypoechoic Wall Edema and Halo Sign

20. Fused PET CT: Increased FDG Uptake in Ascending and Descending Aorta Walls

21. Diagnostic Algorithm for GCA

22. Conventional Treatments

23. Steroids: Not Effective in Long-Term Disease Control (GiACTA)

24. Methotrexate in GCA

25. Infliximab in GCA

26. New Knowledge on Pathophysiology of GCA

27. Emerging Treatments: TCZ

28. Relapse-Free Survival After Stopping TCZ

29. GiACTA Trial

30. Sustained Remission Primary and Key Secondary Endpoints

31. Sensitivity Analysis

32. Time to First Flare Following Clinical Remission

33. Steroid Dosing, Without TCZ

34. TCZ Had Significant Steroid-Sparing Effect

35. Safety Overview

36. IL-12/23 Inhibitor: Ustekinumab

37. IL-23 Inhibitor: Ustekinumab (cont)

38. Ustekinumab: Conclusions

39. Concluding Remarks

40. Abbreviations

41. Abbreviations (cont)